Cre8 EVO™ superior to latest DES in GEC PCI
The DESIGNATE study, an independent multicentre registry in almost 700 consecutive PCIs that have required the use of a Guiding Extension Catheter (GEC), has shown that the use of the polymer-free and abluminal reservoir based Cre8 EVO™ DES provides superior clinical outcome vs. all the latest surfaced coated durable or absorbable polymeric DES (TLF at 1year: 1.1% Cre8 EVO™ vs. 8.1% Other DES; p=0.021).
ENTER
Latest Cre8 EVO™ data just released @ CRT 2026
During the LBT session at CRT2026, the 5 year results of the independent SUGAR RCT in diabetic patients have shown that the superior TLF outcome at 1 year of the CID Cre EVO™ DES vs. Onyx™ DES has been maintained at 5 years (TLF at 1 year: 7.2% Cre8 EVO™ vs. 10.9% Onyx™; p superiority = 0.030. TLF from 1 to 5 years: 6.4% Cre8 EVO™ vs. 6.5% Onyx™)
ENTER
Latest NiTiDES™ data just released @ LINC 2026
The 2 years results of the "All-Comers SFA study" in very complex patients (>15cm average lesion length; 35% severe calcifications; 48,1% CLI) presented by Dr. Cioppa (IT) have confirmed impressive results: Freedom from TLR = 88,3% and 0% HALO!
ENTER
The Cre8™ BTK BX DES takes the stage during LINC 2026!
The need for an effective DES in the BTK setting, where the disease is very complex and the diabetic patients represent the vast majority of those needing a PTA, has shown how the unique Cre8™ BTK technologies & features contribute to long term efficacy & safety.
ENTER
Cre8 EVO™ superior to latest DES in GEC PCI
The DESIGNATE study, an independent multicentre registry in almost 700 consecutive PCIs that have required the use of a Guiding Extension Catheter (GEC), has shown that the use of the polymer-free and abluminal reservoir based Cre8 EVO™ DES provides superior clinical outcome vs. all the latest surfaced coated durable or absorbable polymeric DES (TLF at 1year: 1.1% Cre8 EVO™ vs. 8.1% Other DES; p=0.021).
ENTER
Latest Cre8 EVO™ data just released @ CRT 2026
During the LBT session at CRT2026, the 5 year results of the independent SUGAR RCT in diabetic patients have shown that the superior TLF outcome at 1 year of the CID Cre EVO™ DES vs. Onyx™ DES has been maintained at 5 years (TLF at 1 year: 7.2% Cre8 EVO™ vs. 10.9% Onyx™; p superiority = 0.030. TLF from 1 to 5 years: 6.4% Cre8 EVO™ vs. 6.5% Onyx™)
ENTER
Latest NiTiDES™ data just released @ LINC 2026
The 2 years results of the "All-Comers SFA study" in very complex patients (>15cm average lesion length; 35% severe calcifications; 48,1% CLI) presented by Dr. Cioppa (IT) have confirmed impressive results: Freedom from TLR = 88,3% and 0% HALO!
ENTER
The Cre8™ BTK BX DES takes the stage during LINC 2026!
The need for an effective DES in the BTK setting, where the disease is very complex and the diabetic patients represent the vast majority of those needing a PTA, has shown how the unique Cre8™ BTK technologies & features contribute to long term efficacy & safety.
ENTERWe use cookies to enhance your experience. You can accept, reject, or manage preferences.
